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LETTERS TO THE EDITORThere is no sex equality in carotid disease
In his commentary in the Journal of Vascular Surgery Abstract
section on the article by Henriksson et al,1 which concluded that to
all intents and purposes carotid endarterectomy (CEA) was not
cost-effective in women with asymptomatic carotid disease, Dr
Greg Moneta2 observed that although the data were interesting, it
seemed “politically untenable to deny women, and not men,
prophylactic CEA for high grade asymptomatic stenosis.”
At first sight, this seems a not unreasonable observation, but it
does require the reader to assume that women gain equivalent
clinical benefit (in terms of long term stroke prevention) to men. In
fact, this is not the case. In the original Asymptomatic Carotid
Atherosclerosis Study (ACAS) publication,3 the authors conceded
that CEA did not confer significant benefit in women, with an
absolute risk reduction in ipsilateral stroke of 1.7% at 5 years. Even
when all strokes and deaths occurring in the first 30 days were later
excluded,4 there was still no significant benefit observed in women.
ACST subsequently claimed that CEA conferred significant benefit
in women,5 but this was only the case if the operative risk was
excluded (ie, the 5-year benefits were modelled on a zero percent
procedural risk). Once the procedural risk was included, all signif-
icant benefit in women ceased.6
When the ACAS and Asymptomatic Carotid Surgery Trial
(ACST) data were combined, the Cochrane Collaboration7 per-
formed a subgroup analysis in 1644 women and again noted that
CEA did not significantly reduce the 5-year risk of stroke compared
with best medical therapy (odds ratio, 0.96; 95% confidence interval,
0.63-1.45). The lower magnitude of benefit observed in women is
almost certainly due to a combination of there being a slightly higher
procedural risk compared with men (a consistent finding across all of
the symptomatic and asymptomatic randomized trials and also in a
systematic review of the published literature)8 combined with a lower
late natural history risk of stroke compared with men.
The article by Henriksson et al is undoubtedly a provocative
way of demonstrating the reduced clinical benefit conferred by
CEA in women, and Greg Moneta’s observation will be typical of
many who are intuitively reluctant to treat men and women
differently. More important, until the guideline makers address
this issue, surgeons will remain reluctant to advise against offering
CEA to women because of a very real fear of uncritical medicolegal
censure. This, if nothing else, is another compelling reason for
urging the principle investigators of trials comparing CEA with
carotid stenting in asymptomatic patients to include a medical arm
in the randomization process. Continuing to ignore this important
clinical issue is also neither professionally nor politically tenable.
Professor A. Ross Naylor, MD, FRCS
Leicester Medical School
Department of Cardiovascular Sciences
Vascular Surgery Group
Leicester LE2 7LX, United Kingdom
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Regarding “Carotid artery stenting has increased
rates of postprocedure stroke, death, and resource
utilization than does carotid endarterectomy in the
United States, 2005”
In December 2008, McPhee et al warned about the dangers of
carotid artery stenting (CAS) in increasing risks of perioperative
mortality (1.1% vs 0.57%, P  .04) and stroke (1.8% vs 1.1%, P 
.05; odds ratio [OR] 1.7; 95% confidence interval [CI] 1.2-2.3)
compared with carotid endarterectomy (CEA).1 The warnings,
based on large U.S. coding datasets and published in The Journal
of Vascular Surgery, immediately raised great resonance condemn-
ing CAS. Are these alerts completely justified? At this point we do
not know, since the numbers and the data are not as powerful as
the conclusive words to prove increased mortality and stroke risks.
According to multivariate analysis in the McPhee paper, the
only strong predictors of perioperative mortality were renal
failure (OR 2.7; 95% CI 1.6-4.6, P  .0004) and congestive
heart failure (CHF) (OR 2.8; 95% CI 1.7-4.5, P .0001), these
being the same two baseline factors significantly more frequent
in the CAS vs CEA group (3.9% vs 3%, P  .02 and 11.4% vs
6.8%, P  .0001, for renal failure and CHF in CAS and CEA,
respectively). The higher mortality in CAS patients could be due
to the procedure itself or more realistically, the high fatality rate
was biased by baseline unbalance and a higher proportion of
patients with high fatality risk factors at baseline.
Even if CAS finally passes in the future, the procedure will never
be for all practitioners. It is required that CAS be performed exclu-
sively in centers with specific dedicated experience and adequate
training. Large beds and teaching hospitals may be enough to provide
high medical and surgical standards of care but may not be enough to
ensure safe proficiency with new procedures as CAS. In the McPhee et
al dataset, CAS population was about 10% of the overall population
(90% being CEAs), suggesting that CAS centers were not actively
working and were without large carotid experience. It would be
interesting if the Authors could provide the number of CAS proce-
dures per center (or better, the number of CAS per operators, if data
are available) to provide data on experience and include this in a
multivariate analysis on outcome. With a track record of less than 50
CAS, it is not recommended to perform CAS.2,3
Are CAS and CEA populations, as detected by the coding
datasets, truly representative of the U.S. reality? It is quite unusual
that 90% of CEA were performed in asymptomatic patients and
almost half of the population was female (in other series, females
were about 30% and asymptomatics about 60%).4 These are two
subgroups (asymptomatic and female) of patients for whom treat-
ment of carotid stenosis has been proven to be of lesser benefit,
particularly in U.S. carotid trials (Asymptomatic Carotid Athero-
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Endarterectomy Trial [NASCET]).
Incomplete coded data, unrepresentative of the real world, selec-
tion bias, and type  errors should be taken into account before
spreading alarm. At this time, the available data are not mature
enough to prove or disprove CAS. We should have an open mind
while waiting for the truth to come to light together with more robust
numbers (from randomized clinical trial (RCT) as the final data of
Carotid Revascularization Endarterectomy Versus Stenting Trial
[CREST]) before prematurely condemning the still young but prom-
ising CAS procedure.
Paola De Rango, MD
Gianbattista Parlani, MD
Piergiorgio Cao, MD, FRCS
Division of Vascular and Endovascular Surgery
University of Perugia
Hospital S.M. Misericordia
06100 Perugia, Italy
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Reply
This letter is written in response to the author(s) of the letter
to the editor in which concerns are expressed about our recent
publication in The Journal of Vascular Surgery entitled “Carotid
artery stenting has increased rates of post-procedure stroke, death,
and resource utilization than does carotid endarterectomy in the
United States, 2005.”1 We certainly appreciate their careful review
of our work and would like to address several points raised by the
authors.
In the letter to the editor, the author states that, “we should
have an open mind while waiting for the truth to come to light with
more robust numbers before prematurely condemning the still
young but promising CAS procedure.” Like most practitioners we
too are anxiously awaiting the definitive results from the Carotid
Revascularization Endarterectomy Versus Stenting Trial (CREST)
trial to help shape our practice patterns and we would like to clarify
that our population-based study from the Nationwide Inpatient
Sample (NIS) in 2005 was not meant to “condemn” carotid artery
stenting (CAS). Rather, our purpose was to provide the most
up-to-date, and dispassionate review of the nationwide experi-
ence on post-procedure outcomes for the treatment of carotid
artery stenosis during a year (2005), in which a dedicated
International Classification of Diseases, 9th Edition, Clinical
Modification (ICD-9CM) code existed for CAS. In fact, in
comparing our 2008 work with our previously published data
from previous years,2 we state in the penultimate paragraph of
this article, “Of interest, it seems that over time, the outcomes
for CAS may be improving, and the current work shows that by
2005 the previously large gap between carotid endarterectomy
(CEA) and CAS may be narrowing.”1The letter writer is rightfully concerned about the fact that
“the higher mortality in CAS patients could be due to the proce-
dure itself or more realistically, the high fatality rate biased by
baseline unbalance and a higher proportion of patients with high
fatality risk factors at baseline.” We are in agreement, which is why
we went to great lengths in the discussion to address this likely
unmeasured selection bias from administrative datasets, “We have
attempted to account for certain patient co-morbid medical con-
ditions using validated software, however, this is limited informa-
tion and does not speak to the severity of a patient’s disease state,
which would represent a selection bias whereby the sickest and
highest risk patients likely underwent CAS”1 and “It is important
to recognize that the observations made in this work regarding
mortality, post-procedure stroke and resource utilization related to
CEA and CAS are likely multi-factorial. We are unable to deter-
mine to what extent a patient’s mortality, morbidity, length of stay
(LOS), or hospital charge is directly attributable to the procedure
itself or whether it was related to a pre-existing co-morbidity or
other mitigating factor.”1
We would also agree with the letter writer that, despite our
best efforts, we have not accounted for individual CAS provider-
volume as this information is simply unobtainable from this type of
dataset. We further mention that our observations are “within the
limitations of a large administrative dataset, which include a lack of
comprehensive risk stratification by procedure type.”1 Despite the
expressed shortcomings of using administrative databases, short-
comings that are extensively described in our paper,1 we would like
to point out to the authors that we are not an outlier in our
observations. Our results are congruent with those found in other
population-based works,3 as well as a recent systematic meta-
analysis,4 and a large multi-institutional work5 that was terminated
early due to the interval results in favor of CEA. Despite these
findings, we have tempered our observations with caution and we
agree with the letter writer that the jury is still out on this “young
but promising” procedure and we do not believe that it should be
condemned but rather closely monitored by practitioners from
diverse specialty backgrounds to ensure that its technical feasibility
does not affect its indications for usage in the absence of definitive
data from randomized controlled trials.
Thank you again for carefully reviewing our work, on behalf of
the authors.
James T. McPhee, MD
Mohammad H. Eslami, MD, FACS
UMass Memorial Medical Center
Worcester, Mass
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